Aryl-Urea Class and Related TRPV1 Antagonists

Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

Volumn , Issue , 2010, Pages 293-310

  Gomtsyan, Arthur ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Aryl urea class and related TRPV1 antagonists; Conformationally restricted aryl cinnamides; TRPV1 antagonists and agonists as novel analgesic drugs

Indexed keywords

EID: 84864144816     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470588284.ch11     Document Type: Chapter

References (55)

1. Bayburt EK, Daanen JF, Gomtsyan AR, Latshaw SP, Lee C - H, and Schmidt RG (2008) Antagonists of the TRPV1 receptor and uses thereof. U.S. Patent 20080153871.
2. Besidski Y and Nistrom J - E (2004) New sulfonyl derivatives of aminonaphtols. WO Patent 2004089881.
3. Blurton P, Burkamp F, Fletcher SR, Hollingworth GJ, Jones AB, McIver EG, Moyes CR, and Rogers L (2004) Amino - heterocycles as VR - 1 antagonists for treating pain. WO Patent 2004046133.
4. Broad LM, Keding SJ, and Blanco M - J (2008) Recent progress in the development of selective TRPV1 antagonists for pain. Curr Top Med Chem 8: 1431 - 1441.
5. Brown BS, Koenig JR, Gomtsyan AR, and Lee C - H (2007) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof. WO Patent 2007121299.
6. Brown W, Griffin A, Johnstone S, Labrecque D, Munro A, Pache S, and Walpole C (2006) Preparation of benzothiazole carboxamides for treatment of VR1 mediated disorders. WO Patent 2006068592.
7. Brown W, Johnstone S, and Labrecque D (2008) Benzimidazole derivatives as vanilloid receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO Patent 2008018827.
8. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat - activated ion channel in the pain pathway. Nature 389: 816 - 824.
9. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, Bullman JN, Gray EJ, Lai RY, Williams PM, and Appleby JM (2007) The effects of the TRPV1 antagonist SB - 705498 on TRPV1 receptor - mediated activity and inflammatory hyperalgesia in humans. Pain 132: 132 - 141.
10. Codd E, Dax SL, Jetter M, McDonell M, McNally JJ, and Youngman M (2003) Aminotetralin - derived urea modulators of vanilloid VR1 receptor. WO Patent 2003097586.
11. Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Dyson A, Dziadulewicz EK, Edwards L, Eggelte H, Fox A, Gentry C, Groarke A, Hallett A, Hart TW, Hughes GA, Knights S, Kotsonis P, Lee W, Lyothier I, McBryde A, McIntyre P, Paloumbis G, Panesar M, Patel S, Seiler M - P, Yagoob M, and Zimmerman K (2006) Identification and biological characterization of 6 - aryl - 7 - isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J Med Chem 49: 471 - 474.
12. Doherty EM, Fotsch C, Bannon AW, Bo Y, Chen N, Dominguez C, Falsey J, Gavva NR, Katon J, Nixey T, Ognyanov VI, Pettus L, Rzasa RM, Stec M, Surapaneni S, Tamir R, Zhu J, Treanor JJS, and Norman MH (2007) Novel vanilloid receptor - 1 antagonists: 2. Structure - activity relationships of 4 - oxopyrimidines leading to the selection of a clinical candidate. J Med Chem 50: 3515 - 3527.
13. Doherty EM, Fotsch C, Bo Y, Chakrabarti PP, Chen N, Gavva N, Han N, Kelly MG, Kincaid J, Klionsky L, Liu Q, Ognyanov VI, Tamir R, Wang X, Zhu J, Norman MH, and Treanor JJS (2005) Discovery of potent, orally available vanilloid receptor - 1 antagonists. Structure - activity relationship of N - aryl cinnamides. J Med Chem 48: 71 - 90.
14. Drizin I, Gomtsyan A, Bayburt EK, Schmidt RG, Zheng GZ, Perner RJ, Didomenico S, Koenig JR, Turner SC, Jinkerson TK, Brown BS, Keddy RG, McDonald HA, Honore P, Wismer CT, Marsh KC, Wetter JM, Polakowski JS, Segreti JA, Jarvis MF, Faltynek CR, and Lee C - H (2006) Structure - activity studies of a novel series of 5,6 - fused heteroaromatic ureas as TRPV1 antagonists. Bioorg Med Chem 14: 4740 - 4749.
15. El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee C - H, Honore P, Sullivan JP, Jarvis MF, and Faltynek CR (2005) A - 425619 [1 - isoquinolin - 5 - yl - 3 - (4 - trifluoromethyl - benzyl) - urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther 314: 400 - 409.
16. Fletcher SR, Hollingworth GJ, Jones AB, Moyes CR, and Rogers L (2005) Heteroaromatic ureas which modulate the function of the vanilloid - 1 receptor (VR1). WO Patent 2005028445.
17. Frank R, Bahrenberg G, Christoph T, Schiene K, De Vry J, Saunders D, Przewosny M, Sunderman B, and Lee J (2008) Preparation of N- benzyl- 2- phenylpropanamides as vanilloid receptor antagonists. WO Patent 2008125337.
18. Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, and Treanor JJS (2007) Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 323: 128 - 137.
19. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis J - C, and Treanor JJS (2005) AMG 9810 [(E) - 3 - (4 - t - Butylphenyl) - N - (2,3 - dihydrobenzo[b][1,4]dioxin - 6 - yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313: 474 - 484.
20. Gavva NR, Treanor JJS, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, and Davar G (2008) Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136: 202 - 210.
21. Gharat L and Szallasi A (2007) Medicinal chemistry of the vanilloid (capsaicin) TRPV1 receptor: current knowledge and future perspectives. Drug Dev Res 68: 477 - 497.
22. Gharat LA, Gajera JM, Khairatkar - Joshi N, and Kattige V (2008) Indazole derivatives and their use as vanilloid receptor ligands. WO Patent 2008110863.
23. Gharat LA, Joshi UM, and Joshi NK (2007) Substituted benzofused derivatives and their use as vanilloid receptor ligands. WO Patent 2007042806.
24. Gharat LA and Szallasi A (2008) Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Expert Opin Ther Patents 18: 159 - 209.
25. Gomtsyan A, Bayburt EK, Keddy R, Turner SC, Jinkerson TK, Didomenico S, Perner RJ, Koenig JR, Drizin I, McDonald HA, Surowy CS, Honore P, Mikusa J, Marsh KC, Wetter JM, Faltynek CR, and Lee C - H (2007) a - Methylation at benzylic fragment of N - aryl - N ' - benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model. Bioorg Med Chem Lett 17: 3894 - 3899.
26. Gomtsyan A, Bayburt EK, Schmidt RG, Lee C - H, Brown BS, Jinkerson TK, Koenig JR, Daanen JF, and Latshaw SP (2006a) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof. U.S. Patent 20060128689.
27. Gomtsyan A, Perner R, Koenig J, Hsu MC - P, Fernando D, and Lee C - H (2006b) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof. WO Patent 2006122250.
28. Gomtsyan A, Bayburt EK, Schmidt RG, Surowy CS, Honore P, Marsh KC, Hannick SM, McDonald HA, Wetter JM, Sullivan JP, Jarvis MF, Faltynek CR, and Lee C - H (2008) Identification of (R) - 1 - (5 - tert - butyl - 2,3 - dihydro - 1H - inden - 1 - yl) - 3 - (1H - indazol - 4 - yl)urea (ABT - 102) as a potent TRPV1 antagonist for pain management. J Med Chem 51: 392 - 395.
29. Gomtsyan A, Bayburt EK, Schmidt RG, Zheng GZ, Perner RJ, Didomenico S, Koenig JR, Turner S, Jinkerson T, Drizin I, Hannick SM, Macri BS, McDonald HA, Honore P, Wismer CT, Marsh KC, Wetter J, Stewart KD, Oie T, Jarvis MF, Surowy CS, Faltynek CR, and Lee C - H (2005) Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure - activity relationshipsfor ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J Med Chem 48: 744 - 752.
30. Gunthorpe MJ, Rami JK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, and Davis JB (2004) Identification and characterization of SB - 366791, a potent and selective vanilloid receptor (VR1/ TRPV1) antagonist. Neuropharmacology 46: 133 - 149.
31. Hanazawa T, Nagayama S, Nakao K, Shishido Y, and Tanaka H (2007) Preparation of cyclopropanecarboxamide compounds as vanilloid VR1 receptor antagonists. WO Patent 2007129188.
32. Honore P, Chandran P, Hernandez G, Gauvin D, Mikusa J, Zhong C, Joshi S, Ghilardi J, Sevcik M, Fryer R, Segreti J, Banfor P, Marsh K, Neelands T, Bayburt E, Daanen J, Gomtsyan A, Lee C - H, Kort M, Reilly R, Surowy C, Kym P, Mantyh P, Sullivan J, Jarvis M, and Faltynek C (2009) Repeated dosing of ABT - 102, a potent and selective TRPV1 antagonist, enhances TRPV1 - mediated analgesic activity in rodents, but attenuates antagonist - induced hyperalgesia. Pain 142: 27 - 35.
33. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee C - H, Marsh K, Sullivan JP, Faltynek CR, and Jarvis MF (2005) A - 425619 [1 - isoquinolin - 5 - yl - 3 - (4 - trifluoromethyl - benzyl) - urea], a novel and selective transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 314: 410 - 421.
34. Horoszok L, Leung C, Tomaszewski M, and Walpole C (2007) Use of spiro[imidazolidine - 4,3 ' - indole] - 2,2 ' ,5 ' (1H) - triones for treatment of conditions associated with vanilloid receptor 1 and their preparation and pharmaceutical compositions. WO Patent 2007091946.
35. Jetter MC, Youngman MA, McNally JJ, Zhang S - P, Dubin AE, Nasser N, and Dax SL (2004) N - Isoquinolin - 5 - yl - N ' - aralkyl - urea and - amide antagonists of human vanilloid receptor 1. Bioorg Med Chem Lett 14: 3053 - 3056.
36. Kwak JY, Jung JY, Hwang SW, Lee WT, and Oh U (1998) A capsaicin - receptor antagonist, capsazepine, reduces inflammation - induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin - like substance. Neuroscience 86: 619 - 626.
37. Norman MH, Zhu J, Fotsch C, Bo Y, Chen N, Chakrabarti P, Doherty EM, Gavva NR, Nishimura N, Nixey T, Ognyanov VI, Rzasa RM, Stec M, Surapaneni S, Tamir R, Viswanadhan VN, and Treanor JJS (2007) Novel vanilloid receptor - 1 antagonist: 1. Conformationally restricted analogues of trans - cinnamides. J Med Chem 50: 3497 - 3514.
38. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, Gunthorpe MJ, and Davis JB (2006) Discovery of SB - 705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 16: 3287 - 3291.
39. Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, Chu KL, McDonald HA, Vos M, Niforatos W, Bayburt EK, Gomtsyan A, Lee C - H, Honore P, Sullivan JP, Jarvis MF, and Faltynek CR (2008) (R) - (5 - tert - Butyl - 2,3 - dihydro - 1H - inden - 1 - yl) - 3 - (1H - indazol - 4 - yl)urea (ABT - 102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat - evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther 326: 879 - 888.
40. Szallasi A and Blumberg PM (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159 - 211.
41. Tajimi M, Kokubo T, Shiroo M, Tsukimi Y, Yura T, Yamamoto N, Mogi M, Fujishima H, Masuda T, Yoshida N, and Moriwaki T (2004) Tetrahydro - naphthalene derivatives as vanilloid receptor antagonists. WO Patent 2004052845.
42. Tang L, Chen Y, Chen Z, Blumberg PM, Kozikowski AP, and Wang ZJ (2007) Antinociceptive pharmacology of N - (4 - chlorobenzyl) - N ' - (4 - hydroxy - 3 - iodo - 5 - methoxybenzyl) thiourea, a high - affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. J Pharmacol Exp Ther 321: 791 - 798.
43. Toth A, Blumberg PM, Chen Z, and Kozikowski AP (2004) Design of a high - affinity competitive antagonist of the vanilloid receptor selective for the calcium entry - linked receptor population. Mol Pharmacol 65: 282 - 291.
44. Turner SC, Jinkerson TK, Gomtsyan AR, and Lee C - H (2006) Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof. WO Patent 2006063178.
45. Uchida H, Kosuga N, Satoh T, Hotta D, Kamino T, Maeda Y, Amano K - I, and Akada Y (2007) Preparation of novel 2 - (bicyclic heterocyclidene)acetamide derivatives as antagonists of transient receptor potential type 1 (TRPV1). WO Patent 2007010383.
46. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, and McIntyre P (2003) The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304: 56 - 62.
47. Walpole CS, Bevan S, Bowermann G, Boelsterle JJ, Breckenridge R, Davies JW, Hughes GA, James I, Oberer L, Winter J, and Wrigglesworth R (1994) The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 37: 1942 - 1954.
48. Walpole CSJ and Wrigglesworth R (1993) Structural requirements for capsaicin agonists and antagonists. In Capsaicin in the Study of Pain (Wood JN, ed.), pp. 63 - 82. Academic Press, San Diego, CA.
49. Wang X, Chakrabarti PP, Ognyanov VI, Pettus LH, Tamir R, Tan H, Tang P, Treanor JJS, Gavva NR, and Norman MH (2007) Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility. Bioorg Med Chem Lett 17: 6539 - 6545.
50. Wang H - L, Katon J, Balan C, Bannon AW, Bernard C, Doherty EM, Dominguez C, Gavva NR, Gore V, Ma V, Nishimura N, Surapaneni S, Tang P, Tamir R, Thiel O, Treanor JJS, and Norman MH (2007) Novel vanilloid receptor - 1 antagonists: 3. The identification of a second - generation clinical candidate with improved physicochemical and pharmacokinetic properties. J Med Chem 50: 3528 - 3539.
51. Wang Y, Szabo T, Welter JD, Toth A, Tran R, Lee J, Kang SU, Lee Y - S, Min KH, Suh Y - G, Park M - K, Park H - G, Park Y - H, Kim H - D, Oh U, Blumberg PM, and Lee J (2002) High affinity antagonists of the vanilloid receptor. Mol Pharmacol 62: 947 - 956.
52. Westaway SM (2006) The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem 50: 2589 - 2596.
53. Xiao D, Palani A, Aslanian R, McKittrick BA, McPhail AT, Correll CC, Phelps PT, Anthes JC, and Rindgen D (2008) Spiro - piperidine azetidinones as potent TRPV1 antagonists. Bioorg Med Chem Lett 19: 783 - 787.
54. Yura T, Mogi M, Urbahns K, Fujishima H, Masuda T, Moriwaki T, Yoshida N, Kokubo T, Shiroo M, Tajimi M, Tsukimi Y, and Yamamoto N (2003) Hydroxy tetrahydro - naphthalenylurea derivatives. WO Patent 2003095420.
55. Zhu J, Viswanadhan V, Ognyanov V, Bo Y, Chen N, Chakrabarti P, Doherty E, Fotsch C, Gavva N, Han N, Klionsky L, Liu Q, Tamir R, Wang X, Sun Y, Treanor JJS, and Norman MH (2005) Conformational analyses of N - aryl cinnamides as TRPV1 antagonists. Abstracts of 229th National Meeting of the American Chemical Society, San Diego, CA, March 13 - 17, 2005.